Title:
ＣＤ６６ｃに特異的に結合する抗体およびその用途
Document Type and Number:
Japanese Patent JP7450585
Kind Code:
B2
Abstract:
The present invention relates to an anti-CD66c antibody and its use for treating cancer, and more particularly, it is possible to induce T-cell activation or humoral immune response using an antibody specifically recognizing CD66c. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell and the antibody or antigen-binding fragment thereof is used for alleviation, prevention, treatment or diagnosis of CD66c-related disease.
Inventors:
Yun, Sansun
Hong, Kwon Pyo
Kim, Sosul
Ji Gil Young
Rim, Young Hoon
Hong, Kwon Pyo
Kim, Sosul
Ji Gil Young
Rim, Young Hoon
Application Number:
JP2021118114A
Publication Date:
March 15, 2024
Filing Date:
July 16, 2021
Export Citation:
Assignee:
Kumho HT, Inc.
International Classes:
C12N15/13; A61K39/395; A61K45/00; A61P35/00; A61P35/04; C07K16/30; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63
Domestic Patent References:
| JP2015518826A | ||||
| JP2009106280A |
Foreign References:
| US20110212095 |
Other References:
Acta Biochim Biophys Sin (2014) Vol.46, pp.283-290
Cancer Res (2005) Vol.65, No.19, pp.8809-8817
Cancer Res (2005) Vol.65, No.19, pp.8809-8817
Attorney, Agent or Firm:
Manabu Miyajima
Mari Asano
Hiroshi Sorimachi
Mari Asano
Hiroshi Sorimachi
Previous Patent: Outside air processing equipment
Next Patent: Cold heat recovery system and cold heat utilization method
Next Patent: Cold heat recovery system and cold heat utilization method